306
Participants
Start Date
July 1, 2022
Primary Completion Date
December 30, 2025
Study Completion Date
December 30, 2025
Chidamide
30 mg oral twice weekly for 2 weeks
Cladribine
6 mg/m2 intravenously once daily @ Day -7 \~ -3
Gemcitabine
2500 mg/m2 intravenously @ Day -7, -3
Busulfan
3.2 mg/kg intravenously once daily @ Day -7 \~ -4
Carmustine
300 mg/m2 intravenously @ Day -8
Etoposide
200 mg/m2 intravenously once daily @ Day -7 \~ -4
Cytarabine
400 mg/m2 intravenously once daily @ Day -7 \~ -4
Melphalan
140 mg/m2 intravenously @ Day -3
Autologous hematopoietic stem cell transplant
autologous hematopoietic stem cells infusion after ChiCGB or BEAM chemotherapy
NOT_YET_RECRUITING
Chengdu Third People's Hospital, Chengdu
RECRUITING
West China Hospital, Sichuan University, Chengdu
RECRUITING
Chengdu First People's Hospital, Chengdu
RECRUITING
PLA Western Theater Command General Hospital, Chengdu
NOT_YET_RECRUITING
People's Hospital of Deyang City, Deyang
RECRUITING
Central Hospital of Mianyang City, Mianyang
RECRUITING
Guangyuan Central Hospital, Guangyuan
NOT_YET_RECRUITING
Dazhou Central Hospital, Dazhou
NOT_YET_RECRUITING
Affiliated Hospital of North Sichuan Medical College, Nanchong
RECRUITING
Zigong First People's Hospital, Zigong
RECRUITING
Southwest Medical University, Luzhou
Sichuan University
OTHER